Mobile

A phase II, single-blind, randomized, controlled, multicentre vaccination study to evaluate the safety and immune response of the GSK Biologicals Zoster vaccine, gE/AS01B, and to compare 3 doses of gE...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004863-69

A phase II, single-blind, randomized, controlled, multicentre vaccination study to evaluate the safety and immune response of the GSK Biologicals Zoster vaccine, gE/AS01B, and to compare 3 doses of gE with AS01B adjuvant in healthy elderly subjects, aged 60 to 69 years and 70 years and above

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The main objective of the trial is to compare the CD4 T cell response to gE of gE/AS01B study vaccines at Month 3 in healthy elderly subjects of more than or equal to 70 years of age (YOA).

Critère d'inclusion

  • Primary immunization of healthy elderly subjects (60 to 69 and more than or equal to 70 years) against zoster

Liens